For the past decade, many medical journals have begun requiring contributors to disclose their conflicts of interest, but a new study finds that many journal editors — who are also doctors — themselves receive hefty payments from industry and most of their journals do a poor job of disclosing relevant policies.
To wit, the study found that, in 2014, half of 713 journal editors, whose payments were reported to a U.S. government database, had received something of value from drug or device makers, and nearly 10 percent had received research funding. While the median general payment was only $11, the range was large — from $0 to more than $2,900. And two editors received more than $1 million in payments.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
